Anzeige
Mehr »
Samstag, 25.10.2025 - Börsentäglich über 12.000 News
Gold über 4.000 US-Dollar - Canary Gold startet Multi-Front-Exploration in Brasiliens neuem Gold-Hotspot
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40YEM | ISIN: US19207A2078 | Ticker-Symbol:
NASDAQ
24.10.25 | 21:59
14,780 US-Dollar
-6,75 % -1,070
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
COEPTIS THERAPEUTICS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
COEPTIS THERAPEUTICS HOLDINGS INC 5-Tage-Chart

Aktueller Chart COEPTIS THERAPEUTICS Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
COEPTIS THERAPEUTICS HOLDINGS INC-Investoren interessieren sich auch für diese Wertpapiere
Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial ResultsInitiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of...
► Artikel lesen
Nuvalent, Inc.: Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLCCAMBRIDGE, Mass., July 21, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted...
► Artikel lesen
Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLCAligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the...
► Artikel lesen
QIAGEN N.V. to Release Results for Q3 2025 and Hold WebcastQIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025. Press release date time: Tuesday, November 4, shortly after 22:05...
► Artikel lesen
Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In JapanTOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic...
► Artikel lesen
Kaum Impulse für die Qiagen NV-Aktie (37,58 €)Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 37,58 Euro. Einen minimalen Wertanstieg von 0,17 Prozent zeigt die Kurstafel für der Anteilsschein von Qiagen...
► Artikel lesen
Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business AchievementsRecord quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded...
► Artikel lesen
Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business AchievementsGenerated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position...
► Artikel lesen